Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Intellia has reported results from a phase 2 trial of its gene ... who said the data "underscore[s] the tremendous potential of [the] in vivo CRISPR gene editing therapy" and "sets NTLA-2002 ...

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I'm still ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

According to InvestingPro data, the company maintains ... Successful clinical trials in autoimmune diseases could significantly enhance CRISPR Therapeutics' market position. The company's CTX112 ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... 2025 promises to be a milestone-rich year, with clinical data updates across several programs ...

Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and ...

Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based ... With the promising data we’ve presented ...